UCERIS® /Cortiment® is an oral tablet formulation which delivers budesonide directly to the lumen of the colon. Budesonide is a corticosteroid that acts as an anti-inflammatory pharmaceutical product. It is the active ingredient in a number of treatments for asthma, non-infectious rhinitis (including hay fever and other allergies), nasal polyposis and Crohn's Disease. The specific pharmaceutical product dissolution profile increases the colonic specific bio-availability of budesonide and reduces the pre-colonic systemic absorption. The intended reduction of systemic absorption reduces side effects associated with pharmaceutical product treatment while the intended delivery to the colon enables the product to be especially effective in the treatment of proximal and distal Ulcerative Colitis.
The product is licensed to Salix / Valeant in the US and was approved for marketing under the brand-name of UCERIS® on January 14, 2013 in the US. Ferring has the license for the Rest of the World and received the marketing authorization for The Netherlands under the brand name of Cortiment® on January 31, 2013 and approvals in EU and other countries around the world.